Liver disease in cystic fibrosis

Area of Science:

• Pediatrics
• Hepatology
• Genetics

Background:

• Improved survival in cystic fibrosis (CF) patients due to early diagnosis and advanced care.
• Increased prevalence of non-respiratory complications, particularly liver disease, in the aging CF population.
• Biochemical liver enzyme abnormalities are common in CF, stemming from various hepatobiliary issues.

Purpose of the Study:

• To provide a comprehensive overview of current knowledge regarding liver disease in pediatric patients with cystic fibrosis.
• To explore the clinical significance and impact of Cystic Fibrosis-associated Liver Disease (CFLD).
• To address the uncertainties surrounding the prognostic implications of CFLD on clinical outcomes.

Main Methods:

• Literature review of current research on liver disease in pediatric cystic fibrosis.
• Analysis of studies focusing on Cystic Fibrosis-associated Liver Disease (CFLD) prevalence, diagnosis, and management.
• Synthesis of information on the impact of CFLD on morbidity and mortality in children with CF.

Main Results:

• Cystic Fibrosis-associated Liver Disease (CFLD) is a significant hepatic complication impacting CF patient morbidity and mortality.
• Early diagnosis and improved care have increased CF patient lifespan, highlighting non-respiratory complications like CFLD.
• The precise prognostic impact of CFLD on long-term clinical outcomes remains an area of ongoing research and conjecture.

Conclusions:

• Cystic Fibrosis-associated Liver Disease (CFLD) is a critical concern in pediatric CF care.
• Understanding CFLD's impact is crucial for improving long-term outcomes in children with cystic fibrosis.
• Further research is needed to clarify the prognostic implications of CFLD for better patient management.